Aclaris Therapeutics, Inc.

The company is a clinical-stage biopharmaceutical business that discovers and develops drug candidates for immuno-inflammatory conditions. Its pipeline includes biological therapies such as bosakitug, a monoclonal antibody, and ATI-052, a bispecific antibody targeting inflammatory pathways. It also designs small molecule kinase inhibitors, including ATI-2138 and ATI-9494, using its proprietary drug discovery platform. The company develops these experimental therapies for individuals with autoimmune, dermatological, and respiratory disorders, including atopic dermatitis and asthma, and seeks partnerships with external pharmaceutical firms to advance and commercialize its treatments.

The business relies entirely on third-party contractors to manufacture its preclinical and clinical supplies, maintaining no internal production facilities. Its clinical trial activities and licensing partnerships span international markets, including the United States, Europe, Japan, and South Korea, with global development rights excluding Greater China. The provided document does not identify the location of the company's corporate headquarters.

Summary of the business section of Aclaris Therapeutics's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

“As of December 31, 2025, we had 73 total employees, of which 69 were full-time employees.”